A phase 1 randomized study compare the pharmacokinetics, safety and immunogenicity of HLX04 to reference bevacizumab sourced from the United States, the European Union, and China in healthy Chinese male volunteers
Sign Up to like & getrecommendations! Published in 2021 at "Cancer Chemotherapy and Pharmacology"
DOI: 10.1007/s00280-021-04297-z
Abstract: To compare the pharmacokinetic profiles, safety and immunogenicity of proposed bevacizumab biosimilar HLX04 with reference bevacizumab in healthy Chinese males. In this double-blind Phase 1 study, healthy volunteers (N = 208) were randomized 1:1:1:1 to a single… read more here.
Keywords: bevacizumab; safety; study; hlx04 ... See more keywords
A comparative clinical study of PF-06439535, a candidate bevacizumab biosimilar, and reference bevacizumab, in patients with advanced non-squamous non-small cell lung cancer.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.109
Abstract: 109Background: This ongoing, double-blind, randomized, global clinical trial (NCT02364999) evaluated the efficacy, safety, and immunogenicity of PF-06439535 vs. reference bevacizumab sourced from t... read more here.
Keywords: comparative clinical; bevacizumab; clinical study; reference bevacizumab ... See more keywords